Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425534 | 0.85 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9789186 | 0.83 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8447031 | 0.82 | ALDH1A1 (0.48) | KMT2AKDM4EMEN1LMNASMN1; SMN2 | |
| SCHEMBL104667 | 0.82 | CA12 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3801444 | 0.81 | CA12 (0.40) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12575542 | 0.81 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16888475 | 0.77 | ALDH1A1 (0.42) | KMT2AKDM4EMEN1HTTATM | |
| SCHEMBL1265737 | 0.77 | CA12 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6329502 | 0.77 | CA1 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3027243 | 0.75 | SLC6A9 (0.45) | SLC6A9AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-12-19 | — | — | US | disclosed |
| US-12116351-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-10-15 | — | — | US | disclosed |
| US-20220380322-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-12-01 | — | — | US | disclosed |
| US-11434207-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-09-06 | — | — | US | disclosed |
| CN-108863959-B | P2X4 receptor antagonists | 日本化学药品株式会社 | 2021-11-30 | — | — | CN | disclosed |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2020-07-16 | — | — | US | disclosed |
| CN-111333588-A | P2X4 receptor antagonists | 日本化学药品株式会社 | 2020-06-26 | — | — | CN | disclosed |
| US-10633349-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2020-04-28 | — | — | US | disclosed |
| CN-104066724-B | P2X4 receptor antagonists | 日本化学药品株式会社 | 2020-04-17 | — | — | CN | disclosed |
| US-20180201587-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2018-07-19 | — | — | US | disclosed |
| EP-1694659-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060025453-A1 | Isothiazole dioxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY, INC. | 2006-02-02 | — | — | US | disclosed |
| WO-2005068460-A1 | ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005066147-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-1551818-A1 | THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS | Pharmacopeia Drug Discovery, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1539678-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1, 2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040186142-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC- chemokine receptor ligands | SCHERING CORPORATION PHARMACOPEIA, INC. | 2004-09-23 | — | — | US | disclosed |
| US-20040147559-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004033440-A1 | THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2004-04-22 | — | — | WO | disclosed |
| WO-2004011418-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1, 2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025453-A1 | Isothiazole dioxides as CXC- and CC-chemokine receptor ligands | CCR2, CXCR1, CXCR2 | CA12 1000/4885CA1 452/4885CA2 657/4885 |
| US-20220380322-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | CA12 3280/4885CA1 1429/4885CA2 513/4885 |
| US-20040147559-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, CXCR1, ACKR3 | CA12 1066/4885CA1 1357/4885CA2 2539/4885 |
| US-20040186142-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC- chemokine receptor ligands | CXCR1, CCR2, CX3CR1 | CA12 2248/4885CA1 1189/4885CA2 1738/4885 |
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | CA12 3589/4885CA1 1516/4885CA2 505/4885 |
| US-12116351-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | CA12 3280/4885CA1 1429/4885CA2 513/4885 |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | CA12 3280/4885CA1 1429/4885CA2 513/4885 |
| US-11434207-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | CA12 3280/4885CA1 1429/4885CA2 513/4885 |
| US-10633349-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | CA12 3280/4885CA1 1429/4885CA2 513/4885 |
| US-20180201587-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | CA12 3280/4885CA1 1429/4885CA2 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.